Clinical outcomes from routine practice confirm ocrelizumab effectiveness in relapsing MS, with low rates of disability worsening over 4 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback